Market Overview:

The global high content screening market reached a value of US$ 1.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 1.8 Billion by 2027, exhibiting a CAGR of 8.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries. These insights are included in the report as a major market contributor.

High content screening (HCS), also known as high-content analysis (HCA), is an automated microscopy method of identifying cellular phenotype and biological deviations. It assists in determining whether a drug candidate modifies the disease course and identifying micro-molecules such as peptides or RNAi that alter the cell morphology and phenotype. It is an advanced approach to cell-based screening in drug discovery, which combines the automated recording of multicolor fluorescence imaging and high-throughput quantitative data analysis. It allows professionals to screen and evaluate the activity of compounds on multiple epigenetic marks. As a result, HCS is widely used in pharmaceutical and biotechnology companies, academic and government institutes, and contract research organizations (CROS).

The increasing prevalence of chronic disorders and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, represents one of the major factors positively influencing the demand for HCS around the world. In addition, the rising aging population, which is more prone to such ailments, is contributing to the market growth. Apart from this, leading players are introducing innovative HCS equipment that is integrated with software platforms and artificial intelligence (AI) systems to improve the visualization capabilities of the screening systems. It can also be attributed to the development of automated systems for analyzing cell separation and scalability, which has further improved the adoption of HCS technology. Furthermore, they find extensive application in the pharmaceutical industry due to the escalating need for an affordable drug discovery system. Besides this, governing agencies of numerous countries are considerably investing in the research and development (R&D) of advanced screening systems, along with significant improvement in the healthcare infrastructure, which is creating a positive market outlook. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global high content screening market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on product, application and end-user.

Breakup by Product:

• Instruments
  • Cell Imaging and Analysis Systems
  • Flow Cytometers
• Consumables
  • Reagents & Assay Kits
  • Microplates
  • Other Consumables
• Software
• Services
• Accessories
   

Instruments dominate the market due to advances in instrumentation and automation techniques with advanced visualization capability and enhanced software platforms.

Breakup by Application:

• Target Identification and Validation
• Primary Screening and Secondary Screening
• Toxicity Studies
• Compound Profiling
• Other Applications
   

Primary screening and secondary screening currently dominates the market as primary screening helps in determining the microorganisms and organic acid in cells, whereas secondary screening assists in obtaining the quantitative and qualitative information about the cells, desired organisms or strains.

Breakup by End-User:

• Pharmaceutical and Biotechnology Companies
• Academic and Government Institutes
• Contract Research Organizations (CROs)
   

High content screening (HCS) is widely utilized in pharmaceutical and biotechnology companies for various clinical and preclinical studies.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America holds the majority of the global high content screening share due to the increasing drug discovery research in the region.

Competitive Landscape:

The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, General Electric, Merck KGaA, PerkinElmer, Inc., Perkinelmer Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Yokogawa India Ltd.

Report Coverage:

Key Questions Answered in This Report:

• How has the global high content screening market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What has been the impact of COVID-19 on the global high content screening market?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end-user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global high content screening market and who are the key players?
• What is the degree of competition in the industry?